PF-4708671

Licensed and Manufactured by Pfizer Catalog No.S2163

Molecular Weight(MW): 390.41

PF-4708671 is a cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) with K_i/IC50 of 20 nM/160 nM in cell-free assays, 400-fold greater selectivity for S6K1 than S6K2, and 4- and >20-fold selectivity for S6K1 than MSK1 and RSK1/2, respectively. First S6K1-specific inhibitor to be reported.

Cited by 14 Publications

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Oncogene, 2019, 38(35):6270-6282

PubMed: 31316145 ( click the link to review the publication )

Platelets, 2019, 30(2):241-250

PubMed: 29257917 ( click the link to review the publication )

Nutr Metab (Lond), 2018, 10.1186/s12986-018-0268-9

PubMed: 29743930 ( click the link to review the publication )

Cell Death Dis, 2017, 8(1):e2553

PubMed: 28079897 ( click the link to review the publication )

Front Immunol, 2017, 7:685

PubMed: 28138329 ( click the link to review the publication )

Oncotarget, 2016, 7(8):9163-74

PubMed: 26824321 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(3):799-809

PubMed: 25573956 ( click the link to review the publication )

J Biol Chem, 2015, 290(9):5592-605

PubMed: ( click the link to review the publication )

Cell Signal, 2015, 27(11):2191-200

PubMed: 26210887 ( click the link to review the publication )

Toxicol Lett, 2015, 233(2):102-113

PubMed: 25597859 ( click the link to review the publication )

Cell Immunol, 2015, 298(1-2):9-17

PubMed: 26302934 ( click the link to review the publication )

PLoS One, 2014, 9(2):e90388

PubMed: 24587347 ( click the link to review the publication )

Oncotarget, 2014, 5(10):3145-58

PubMed: 24762669 ( click the link to review the publication )

5 Customer Reviews

After treated with PF-4708671 (PF, 10 uM) and 4EGI-1 (50 uM) for 48 h, GRP78 and ATF4 in QBC939, RBE and HCCC-9810 cells were analyzed using western blot.

PLoS One 2014 9(2), e90388. PF-4708671 purchased from Selleck.
(F) EGR-2 and GFI-1 abundance (n = 5).

Front Immunol, 2017, 7:685. PF-4708671 purchased from Selleck.
Tumor sections were examined for DNA fragmentation (TUNEL) or stained with Ki-76 antibody. The representative images are shown. The brown color indicates the positively stained cells; scale bar, 50 mm.

Mol Cancer Ther, 2015, 14(3): 799-809. PF-4708671 purchased from Selleck.
C. Cell lines were treated with the indicated compounds for 24h. ABC cells are colored in red. GCB are colored in blue. Intermediate cells are colored in gray.

Oncotarget, 2016, 7(8):9163-74. PF-4708671 purchased from Selleck.
Effect of PF-4708671 on lipid accumulation and expression of lipogenic genes in HepG2 cells. Cells were exposed to 6 μM PF-4708671, 144 μM PA (sodium palmitate), or 14 nM RAPA (Rapamycin) for different periods of time. (b) The intracellular lipid content in each group was quantified. (c) Detection of TG levels.

Nutr Metab (Lond), 2018, 15:31. PF-4708671 purchased from Selleck.

Purity & Quality Control

Choose Selective S6 Kinase Inhibitors

Biological Activity

Description

Targets

p70 S6K1 ^[1]
(Cell-free assay)

160 nM

In vitro

PF-4708671 is a piperazinyl-pyrimidine analogue and the first S6K1-specific inhibitor. PF-4708671 does not significantly inhibit the activity of the closely related S6K2 isoform or a number of other AGC kinases (Akt1, Akt2, PKA, PKCα, PKCϵ, PRK2, ROCK2, RSK1, RSK2 or SGK1) . PF-4708671 prevents the S6K1-mediated phosphorylation of S6 protein in response to IGF-1 (insulin-like growth factor 1), while having no effect upon the PMA-induced phosphorylation of substrates of the highly related RSK (p90 ribosomal S6 kinase) and MSK (mitogen- and stress-activated kinase) kinases. PF-4708671 is also found to induce phosphorylation of the T-loop and hydrophobic motif of S6K1, an effect that is dependent upon mTORC1 (mTOR complex 1). PF-4708671 does not affect activity of mTORC1. ^[1]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
BHT-101	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYPJR\|UxRTBwOEKwNlQh\|ryP	MnTkV2FPT0WU
UACC-893	Mkj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWLoRlFHUUN3ME21MlE6QDh4IN88US=>	M{XJc3NCVkeHUh?=
A427	NWOybGh7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXfKR\|hXUUN3ME21MlczPTZ5IN88US=>	NUjkellWW0GQR1XS
OCUB-M	MlzjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH7EclZKSzVyPU[uOlYyODJizszN	MUPTRW5ITVJ?
SW684	MkfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlXyTWM2OD15LkWyNlY5KM7:TR?=	MmTXV2FPT0WU
SK-LMS-1	MkPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVTJR\|UxRTlwMEGzNFIh\|ryP	MX3TRW5ITVJ?
CP50-MEL-B	M4jNNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWPJR\|UxRTlwM{C0NVkh\|ryP	Mn71V2FPT0WU
NCI-H1651	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUfvZ4F{UUN3ME2xNE4xOjd4IN88US=>	M4fZWnNCVkeHUh?=
ABC-1	MkTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnKwTWM2OD1zMD6xNFM4KM7:TR?=	MnvxV2FPT0WU
OE19	NFrwd3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoPiTWM2OD1zMD6xO\|M{KM7:TR?=	M1XiZnNCVkeHUh?=
DSH1	NEnPWolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX;JR\|UxRTFyLki4O\|kh\|ryP	NXXweop1W0GQR1XS
SW13	M3zJUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH7QeYJKSzVyPUGxMlk{OTlizszN	NXfHenpTW0GQR1XS
MDA-MB-453	MlHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGjMSXdKSzVyPUGyMlE3ODNizszN	MXjTRW5ITVJ?
647-V	NVjCWI03T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnvrTWM2OD1zMj6zOVgzKM7:TR?=	MnHtV2FPT0WU
NCI-H2342	NHz1RY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVG1SIlGUUN3ME2xNk4{QTl3IN88US=>	M33qN3NCVkeHUh?=
LB2241-RCC	M3\sT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmHoTWM2OD1zMj61O\|c6KM7:TR?=	NX32Z3hKW0GQR1XS
UACC-257	Ml\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV3JR\|UxRTF\|LkS0OVMh\|ryP	MYfTRW5ITVJ?
NCI-H661	NUi4bGY1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYTJR\|UxRTF\|Lk[0OFkh\|ryP	MmjmV2FPT0WU
FADU	NYHscG5XT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmO3TWM2OD1zMz62PVkzKM7:TR?=	NIKxNZpUSU6JRWK=
A2780	NF;uTXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX\JR\|UxRTF\|LkiwOFEh\|ryP	M3HvbnNCVkeHUh?=
NCI-H1793	NWHyTHpYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2TscWlEPTB;MUSuOFA5PSEQvF2=	MU\TRW5ITVJ?
TE-8	NHHsSVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmTpTWM2OD1zNT6zOFY2KM7:TR?=	NYTFfmp{W0GQR1XS
HGC-27	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkHsTWM2OD1zNj6xOlQ1KM7:TR?=	MYLTRW5ITVJ?
MMAC-SF	NHTDRnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NULZT3RVUUN3ME2xO{4{PzJ5IN88US=>	NFWx[G9USU6JRWK=
Calu-6	M1XPdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4jnZmlEPTB;MUiuNVUyOyEQvF2=	NGDMe29USU6JRWK=
HUTU-80	M1ux[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWfGPWVsUUN3ME2xPE4{QTV7IN88US=>	MmDxV2FPT0WU
SAS	M37a[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVfJR\|UxRTF6Lk[0OVUh\|ryP	M4naN3NCVkeHUh?=
IST-MES1	NIflOGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVnZO2pYUUN3ME2xPE43PTB6IN88US=>	NVrxZWx3W0GQR1XS
C3A	NXq3PIhiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWTvRWJWUUN3ME2xPE44QTF7IN88US=>	NVmxSmNkW0GQR1XS
ES3	NFzrSFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTF6LkizOlQh\|ryP	MU\TRW5ITVJ?
HSC-2	M3;zSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVjBOZBqUUN3ME2xPU43PTRzIN88US=>	MWDTRW5ITVJ?
T47D	NFH1VVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MliwTWM2OD1{MD6xOFg2KM7:TR?=	NXfQZ21RW0GQR1XS
EW-7	NUXl[lBMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX3JR\|UxRTJyLki1PFgh\|ryP	MlTGV2FPT0WU
LN-405	M3j3O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX;WS4VRUUN3ME2yNE45QTZ3IN88US=>	NIG2WlRUSU6JRWK=
U031	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnnBTWM2OD1{MT60PFAzKM7:TR?=	MlziV2FPT0WU
A549	M3LmdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFHVNGJKSzVyPUKxMlg1QTFizszN	MlvzV2FPT0WU
RMG-I	NFW0WIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mlz2TWM2OD1{Mj6yOlY5KM7:TR?=	NF3pVmJUSU6JRWK=
BT-474	M{fGUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVPJR\|UxRTJ{Lk[1OVEh\|ryP	NVPFXlhsW0GQR1XS
NB69	NHrTS2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH3ZcXVKSzVyPUKzMlE2OiEQvF2=	NITuVpdUSU6JRWK=
NB7	Mk\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXLJR\|UxRTJ2LkG4PEDPxE1?	NVXoUWV6W0GQR1XS
HCC1569	NF:4S5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{fETWlEPTB;MkSuOlEzPSEQvF2=	Mn3XV2FPT0WU
MEL-JUSO	MoTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4DV[WlEPTB;MkSuOlkxQCEQvF2=	NY\lW2tzW0GQR1XS
MDA-MB-175-VII	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUHJR\|UxRTJ3LkK1NVch\|ryP	M1TvOHNCVkeHUh?=
HCC1419	NF3SPIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVXh[ph4UUN3ME2yOU43ODB\|IN88US=>	M1rSd3NCVkeHUh?=
Ca9-22	NXXuTnF5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1;MS2lEPTB;MkWuOlQ{OiEQvF2=	Mn[wV2FPT0WU
KGN	NX\HPYp1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEjCfoRKSzVyPUK1Mlc2PDdizszN	MWfTRW5ITVJ?
LB373-MEL-D	NUPkcFFXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWfqS3FRUUN3ME2yOk4yQTN6IN88US=>	MXfTRW5ITVJ?
NCI-H1755	NVvpOmR{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVvJR\|UxRTJ4Lki4OFEh\|ryP	MWDTRW5ITVJ?
D-423MG	NFKxZolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{DJSGlEPTB;MkeuNFcyPSEQvF2=	NFnocolUSU6JRWK=
DK-MG	NGfFWZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYnO[HpiUUN3ME2yPE44QDR4IN88US=>	M3GxSHNCVkeHUh?=
NCI-H1623	M{TWSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmDYTWM2OD1{OD64N\|QzKM7:TR?=	MkfpV2FPT0WU
KU-19-19	M1vBe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGLDfHlKSzVyPUK4Mlk6PSEQvF2=	NYnCOWJSW0GQR1XS
C-33-A	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWrJR\|UxRTJ7LkKxPVgh\|ryP	MXfTRW5ITVJ?
SCC-4	NUPKVJFXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYDJR\|UxRTNyLkOzOVQh\|ryP	MlTjV2FPT0WU
MG-63	NHvHdFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXHJR\|UxRTNyLkW5PVQh\|ryP	NH3ObIdUSU6JRWK=
LNCaP-Clone-FGC	MlL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NETrNHNKSzVyPUOxMlQ6OjFizszN	NH\6TmhUSU6JRWK=
CAPAN-1	M4DhZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYj6T3p[UUN3ME2zNU42Ojh4IN88US=>	MnThV2FPT0WU
GI-ME-N	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTNzLkWzOVMh\|ryP	M1nGdXNCVkeHUh?=
RERF-LC-MS	NWPpXYJXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVfJR\|UxRTN{Lk[3OFch\|ryP	M3;STXNCVkeHUh?=
KLE	M{\ic2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYf0R3c4UUN3ME2zN{41OzN2IN88US=>	MVnTRW5ITVJ?
KNS-81-FD	NVzKSWlKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnLJTWM2OD1\|Mz61NFA5KM7:TR?=	MkTyV2FPT0WU
DOK	MoTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXLJR\|UxRTN2Lk[2NVIh\|ryP	M1TQe3NCVkeHUh?=
ACHN	NEX5NoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVHxd4VHUUN3ME2zOU4yPTh6IN88US=>	NIiwZXJUSU6JRWK=
KYSE-520	NGH4cWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{fCSWlEPTB;M{WuNlM3OSEQvF2=	M{\qUnNCVkeHUh?=
SBC-5	NW[5[\|FET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmTRTWM2OD1\|NT61NVE3KM7:TR?=	MYjTRW5ITVJ?
NCI-H28	MlTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX7MZ\|JqUUN3ME2zOU43Pjl3IN88US=>	M4fkOnNCVkeHUh?=
ES7	NIKwfnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF\STZhKSzVyPUO2MlIzPDlizszN	MoLmV2FPT0WU
A172	MkfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn7qTWM2OD1\|Nj60NVg4KM7:TR?=	NF7Fe3pUSU6JRWK=
UM-UC-3	NVHpR4VMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGfRN5BKSzVyPUO3Mlg4PDZizszN	NGryOWZUSU6JRWK=
LXF-289	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{\NSmlEPTB;M{iuNFA1PyEQvF2=	MWDTRW5ITVJ?
KP-4	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2[wbGlEPTB;M{iuOFc{QSEQvF2=	MYfTRW5ITVJ?
TE-1	NWrDZ3M5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXfJR\|UxRTN7Lk[1PFkh\|ryP	M4DjTXNCVkeHUh?=
G-402	Mlu5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn\hTWM2OD12MD6wOlEh\|ryP	NWr6e3ZrW0GQR1XS
786-0	NFvjcoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2ntcmlEPTB;NECuPVA6PiEQvF2=	Ml72V2FPT0WU
K5	NY\MNHd3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1vs[GlEPTB;NEGuN\|Y5PiEQvF2=	M4PwT3NCVkeHUh?=
SK-N-DZ	MnvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1\ZVWlEPTB;NEGuN\|gzOyEQvF2=	NEX4T4hUSU6JRWK=
OVCAR-4	NHnJO4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlTFTWM2OD12MT63OVY5KM7:TR?=	MkPWV2FPT0WU
T84	NHvXWYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkjvTWM2OD12Mj6xNlY{KM7:TR?=	M17FeXNCVkeHUh?=
GCIY	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlPhTWM2OD12Mz6wPFA{KM7:TR?=	M1X2UXNCVkeHUh?=
BB49-HNC	NGX0bYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUXJR\|UxRTR\|LkOzOFgh\|ryP	M3K4U3NCVkeHUh?=
SNU-C2B	M171dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoX0TWM2OD12Mz62OFM3KM7:TR?=	MUnTRW5ITVJ?
TE-6	NF;ScGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1\HW2lEPTB;NEOuPFg6PCEQvF2=	NYiwfG8yW0GQR1XS
23132-87	NX30fm5NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYLJR\|UxRTR2LkK5O\|gh\|ryP	M2LHXXNCVkeHUh?=
DMS-53	NHvaVZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG[1Z5VKSzVyPUS0MlM{QDRizszN	MW\TRW5ITVJ?
ONS-76	M4q1SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXTVeGplUUN3ME20OE44PjZzIN88US=>	NUXURnZyW0GQR1XS
DMS-273	M1PkUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3q2OGlEPTB;NESuPVQ{KM7:TR?=	MmXQV2FPT0WU
COLO-824	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFjzdVRKSzVyPUS1Mlg4PzVizszN	MnLuV2FPT0WU
DMS-114	NYDGNWlJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFzNR41KSzVyPUS1Mlg6OjdizszN	MVnTRW5ITVJ?
YKG-1	M4nz[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGjoSoFKSzVyPUS2MlA{PTVizszN	MYXTRW5ITVJ?
RH-18	MnTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmTSTWM2OD12Nj6zO\|M{KM7:TR?=	M4rrVnNCVkeHUh?=
NCI-H1355	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn7sTWM2OD12Nj62NVgh\|ryP	NFu2PJpUSU6JRWK=
NCI-H2170	M4PpS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH3ZPIdKSzVyPUS3Mlc2QDRizszN	M3vySHNCVkeHUh?=
OC-314	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MojwTWM2OD12Nz64OFc5KM7:TR?=	NHvKeI9USU6JRWK=
NCI-H2030	M{fmcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVrJR\|UxRTR5Lki5NFYh\|ryP	MnXuV2FPT0WU
22RV1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHjhUVZKSzVyPUS3MlkxOTVizszN	NGrvO5BUSU6JRWK=
G-401	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NULsPHpoUUN3ME20PE41PDF3IN88US=>	NHexdFVUSU6JRWK=
YAPC	MojtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{nrOGlEPTB;NEmuPFA4OyEQvF2=	NED5c2ZUSU6JRWK=
SW1573	MkLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NE\NNnVKSzVyPUWwMlI1OzVizszN	M1WwVXNCVkeHUh?=
COLO-792	NWH0OZZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWXJR\|UxRTVyLk[yN\|ch\|ryP	NVzCPVlUW0GQR1XS
KNS-62	M2\lPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mnj5TWM2OD13MD63OVA5KM7:TR?=	NGPpXmJUSU6JRWK=
NB5	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3fxeGlEPTB;NUGuOFUxQSEQvF2=	M1PKOHNCVkeHUh?=
CP66-MEL	NF3nOGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mny2TWM2OD13MT62OFA5KM7:TR?=	NFf2d5NUSU6JRWK=
CaR-1	M4rIS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXvJR\|UxRTV{LkC2NFYh\|ryP	NGniWVhUSU6JRWK=
CAL-54	NFTRe41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mk\OTWM2OD13Mj6xNVAzKM7:TR?=	MVjTRW5ITVJ?
8305C	NH\GV\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mor6TWM2OD13Mj6zNVUh\|ryP	NH7lRpVUSU6JRWK=
Calu-3	NVH2NJQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUH4RXBJUUN3ME21Nk4{PzN\|IN88US=>	NFO0XopUSU6JRWK=
AU565	NELSR4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkmzTWM2OD13Mj61OVA6KM7:TR?=	M1GwcHNCVkeHUh?=
CW-2	NVnvO45KT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV\JR\|UxRTV{Lki2OVQh\|ryP	M4fCWHNCVkeHUh?=
BEN	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHXZUJJKSzVyPUWzMlc5PjJizszN	NHT4O5hUSU6JRWK=
NCI-H1975	M1P6O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX3yeGZZUUN3ME21N{45QTZ4IN88US=>	MVnTRW5ITVJ?
HCT-116	NVvkXXNHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIXiWY5KSzVyPUW0MlA{OjdizszN	M3zTe3NCVkeHUh?=
SH-4	M2riNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkjVTWM2OD13ND6xN\|gh\|ryP	Mkn6V2FPT0WU
NCI-H1693	NYjJfWVDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmKzTWM2OD13ND6yNVA{KM7:TR?=	NWDsPWxxW0GQR1XS
BPH-1	NV;pWFZxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2jvT2lEPTB;NUWuNlg6OiEQvF2=	NVP1ZYI4W0GQR1XS
CAMA-1	MnvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHSwbpFKSzVyPUW1MlgyOTZizszN	MknnV2FPT0WU
A388	M1;reWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4HPSWlEPTB;NU[uNFk5PSEQvF2=	MonMV2FPT0WU
C2BBe1	NHjTZpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoO4TWM2OD13Nj6yOlM1KM7:TR?=	MWXTRW5ITVJ?
GAMG	M2TKV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3PsemlEPTB;NU[uOVk2PSEQvF2=	M3;pT3NCVkeHUh?=
MKN28	MmL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1zPb2lEPTB;NU[uPFAyOyEQvF2=	NFm4OYhUSU6JRWK=
VA-ES-BJ	MlK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHTlSHlKSzVyPUW2Mlg4PDVizszN	MX;TRW5ITVJ?
HuCCT1	M4CwTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3v6emlEPTB;NUeuNFQ6OiEQvF2=	NU\oPGszW0GQR1XS
BFTC-905	NWfIOIE5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYrJR\|UxRTV5LkK4PVgh\|ryP	NF;qem1USU6JRWK=
LS-123	NXLMXVNJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHLIU5ZKSzVyPUW3MlU3PjhizszN	MVjTRW5ITVJ?
LB996-RCC	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2D5[GlEPTB;NUiuNFI5PyEQvF2=	M1LGXXNCVkeHUh?=
NCI-H1048	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUXIWGkzUUN3ME21PE4zOTh6IN88US=>	MYPTRW5ITVJ?
COR-L105	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWjJR\|UxRTV6LkezN\|ch\|ryP	NXXMUXY1W0GQR1XS
OVCAR-8	M2DiO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4HP[WlEPTB;NUmuNVcyPiEQvF2=	NITwWXhUSU6JRWK=
SK-N-FI	NYSzb2JtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF;sZmxKSzVyPUW5MlMzODdizszN	M{XvSXNCVkeHUh?=
MES-SA	NH7lVJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV:zdHBxUUN3ME21PU41PTB7IN88US=>	M3XmfHNCVkeHUh?=
SCC-9	NH\qcXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlPkTWM2OD13OT60O\|U{KM7:TR?=	NYHabZM5W0GQR1XS
EFO-27	M4G2O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkDCTWM2OD13OT65OFMh\|ryP	MYnTRW5ITVJ?
GT3TKB	NH20eZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoHaTWM2OD14MD62NFQ5KM7:TR?=	NIjOdnJUSU6JRWK=
HCC38	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{PWdmlEPTB;NkGuOFM4QSEQvF2=	MVjTRW5ITVJ?
MLMA	M4jkR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoToTWM2OD14MT62NVY{KM7:TR?=	MWDTRW5ITVJ?
D-566MG	M1[zVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGe2[mhKSzVyPU[zMlUzOjRizszN	MlvuV2FPT0WU
SF295	M2\T[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnnUTWM2OD14Mz62OlU2KM7:TR?=	MkjWV2FPT0WU
ES4	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXHzNFkzUUN3ME22OE41PzF7IN88US=>	NEPIR4VUSU6JRWK=
CAKI-1	MorsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2XYdWlEPTB;NkSuOVczOSEQvF2=	MUnTRW5ITVJ?
OAW-28	NFTsW3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXHvbJRWUUN3ME22OE46PjR5IN88US=>	NWnncXhOW0GQR1XS
NCI-H460	M1;jOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFTwXpZKSzVyPU[1MlA5QTdizszN	MoXSV2FPT0WU
JAR	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUHJR\|UxRTZ3LkW1NVYh\|ryP	MU\TRW5ITVJ?
SNU-449	MonLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXXJR\|UxRTZ3Lke2NVYh\|ryP	MVPTRW5ITVJ?
D-392MG	NGLHWm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnrZTWM2OD14NT65OFM1KM7:TR?=	M4KySnNCVkeHUh?=
EW-22	M1ruXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIPxXZFKSzVyPU[2MlM6PSEQvF2=	M{jqW3NCVkeHUh?=
GCT	NI\qcmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4\ZVmlEPTB;NkeuNFQ1OyEQvF2=	NYTERZAyW0GQR1XS
NOS-1	NETEO\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2G4R2lEPTB;NkeuOlg3PyEQvF2=	M3;he3NCVkeHUh?=
RH-1	NX3QdoZoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIf6[5hKSzVyPU[4MlU2PTlizszN	MkXyV2FPT0WU
HuH-7	NEfBVYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFrBfpZKSzVyPU[5MlExODJizszN	M2flb3NCVkeHUh?=
NUGC-3	NWfCSnRmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXjJR\|UxRTdyLkm2OFQh\|ryP	NFPUVFlUSU6JRWK=
IST-SL1	M1;nSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVLkN4QzUUN3ME23NU4zOzJ2IN88US=>	MnvoV2FPT0WU
SHP-77	Mm[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX;JR\|UxRTd{LkGxPUDPxE1?	NIq3eGhUSU6JRWK=
SW1116	M13pS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEHpWGtKSzVyPUeyMlE1ODdizszN	NEPOdHFUSU6JRWK=
LK-2	NXPQSXU3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1vsW2lEPTB;N{KuPFYyOiEQvF2=	NHPxVHJUSU6JRWK=
U-2-OS	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn3uTWM2OD15Mz6xPFI5KM7:TR?=	M3\MTHNCVkeHUh?=
KYSE-150	MkjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2fOV2lEPTB;N{OuOlEyQCEQvF2=	NEHr[2FUSU6JRWK=
U251	NV7TcoRsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{TCfWlEPTB;N{OuPFE3QCEQvF2=	M2DHT3NCVkeHUh?=
HT-1080	NVPpTYxMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVLnRopNUUN3ME23OE4zPTd2IN88US=>	NGPGZZRUSU6JRWK=
NCI-H1437	M3KwRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXPyVoVlUUN3ME23OE43OzJ4IN88US=>	MYrTRW5ITVJ?
HPAF-II	NUnGe2hKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV6yVJY2UUN3ME23OE43PDF3IN88US=>	Mn7WV2FPT0WU
Becker	M3XWc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV7NVGlyUUN3ME23OU4yOTB3IN88US=>	Mk\2V2FPT0WU
PANC-10-05	NVLadGl5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYTUToJQUUN3ME23OU4zQDZ3IN88US=>	MUnTRW5ITVJ?
TYK-nu	NXr3RVNLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH7ZWZdKSzVyPUe1MlMyODJizszN	M{i4fnNCVkeHUh?=
SKG-IIIa	M4f3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NE[1dm1KSzVyPUe1MlM{PDFizszN	NGT2O2RUSU6JRWK=
NCI-H1993	M4r6XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGPJRZVKSzVyPUe1Mlc{QTdizszN	MXzTRW5ITVJ?
S-117	NV\rZVBpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4O0e2lEPTB;N{WuO\|U2KM7:TR?=	M1TXWXNCVkeHUh?=
HuO9	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnq3TWM2OD15Nj6wNFQ5KM7:TR?=	MkHRV2FPT0WU
CAL-51	NG\wPWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvSTWM2OD15Nj6xNFA3KM7:TR?=	MYfTRW5ITVJ?
BT-20	MoDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmroTWM2OD15Nj6yNVY5KM7:TR?=	MmX1V2FPT0WU
LB831-BLC	NXz5VYJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mk\UTWM2OD15Nj6zNlE4KM7:TR?=	M4PpfHNCVkeHUh?=
LB1047-RCC	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MojPTWM2OD15Nj63OlE6KM7:TR?=	MXzTRW5ITVJ?
ES8	M1z6bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1LYSmlEPTB;N{iuNFA4OyEQvF2=	NUHwWoNYW0GQR1XS
UMC-11	NVTteVF4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlrlTWM2OD15OD6wPFg1KM7:TR?=	MVXTRW5ITVJ?
NCI-H226	M3zhb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnfHTWM2OD15OD6xN\|E2KM7:TR?=	MmLSV2FPT0WU
IGROV-1	MljUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkjFTWM2OD15OD61OVUh\|ryP	MX3TRW5ITVJ?
BHY	NEjQUJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX3kVFBiUUN3ME23PU42QTZizszN	MX;TRW5ITVJ?
MKN45	NFXmWnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3ywVmlEPTB;OECuN\|E4PCEQvF2=	MkmzV2FPT0WU
IA-LM	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{XFUmlEPTB;OECuN\|UyOSEQvF2=	M1e1cXNCVkeHUh?=
WM-115	M1Tj[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M12yRmlEPTB;OEGuOFEyPCEQvF2=	NXXGW4R7W0GQR1XS
VMRC-RCZ	NFXVbnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFvrVldKSzVyPUixMlQ1OjVizszN	MnPkV2FPT0WU
NCI-H2291	NIK1dopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGfzO2RKSzVyPUixMlY5PDJizszN	NF\JcY5USU6JRWK=
MCF7	M4nPcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnvkTWM2OD16Mz6yPFk4KM7:TR?=	M3rBPXNCVkeHUh?=
639-V	Mk\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUXJR\|UxRTh2Lk[xNlkh\|ryP	NWnzRohWW0GQR1XS
RT4	MofWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml\RTWM2OD16NT6yOFA{KM7:TR?=	NFTUVoVUSU6JRWK=
NCI-H2405	MmjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYjJR\|UxRTh3LkK5PVch\|ryP	M4rzXnNCVkeHUh?=
CAL-33	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{HvOmlEPTB;OEWuOlMyPSEQvF2=	NFf3fmFUSU6JRWK=
BT-549	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3XLcGlEPTB;OEWuPVM5OiEQvF2=	MV3TRW5ITVJ?
HT-1197	MnflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV;JR\|UxRTh6LkGwO\|ch\|ryP	MkW1V2FPT0WU
G-361	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXTGZlMzUUN3ME24PE4yPDd2IN88US=>	NFrGNVhUSU6JRWK=
LS-411N	NE\2dYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH;kUFZKSzVyPUi5MlM{QDhizszN	MlXEV2FPT0WU
HT-144	NWDLXotFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUnxOGppUUN3ME24PU42QTl{IN88US=>	NF;vbXNUSU6JRWK=
DJM-1	NEnm[XBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1Xy[WlEPTB;OEmuPFg1PSEQvF2=	M32yW3NCVkeHUh?=
CAL-12T	NVXIOXRRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkjhTWM2OD17MD63PFk2KM7:TR?=	NGDMOm9USU6JRWK=
MKN7	NGT6RmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTlzLkO1OVEh\|ryP	MnHLV2FPT0WU
HuP-T3	M17lTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{n5O2lEPTB;OU[uNVAxPCEQvF2=	Mn3nV2FPT0WU
SK-MG-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXW4[FNuUUN3ME25Ok4yOzR6IN88US=>	M1ntWnNCVkeHUh?=
NCI-H2347	Ml3hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUHGNWVuUUN3ME25PE4yODR{IN88US=>	NILTfVFUSU6JRWK=
SW872	MmHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVS5[Vk2UUN3ME2xNFAvPDV4IN88US=>	NGL6[oVUSU6JRWK=
COLO-829	M2ruZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NULodHB{UUN3ME2xNFAvPTV\|IN88US=>	NYPsepRRW0GQR1XS
MC-IXC	NHPteYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGjDN5NKSzVyPUGwNE43OTVizszN	NGjlXHVUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pS6 / S6 / pS6K / S6K1 / pAKT / AKT ; PubMed: 28626016 J Neurosci Western blot of cell lysates from neurons treated with PF-4708671, rapamycin, and Torin-2, individually or in combination for the indicated times. p-mTOR / mTOR / p-p70S6K / p70S6K ; PubMed: 30423811 Int J Mol Sci As determined using Western blotting, the phospho-p70S6K (p-p70S6K) inhibitor (PF-4708671) reduced the expression of phospho-mTOR (p-mTOR) and p-p70S6K in SCC-4 and SCC-25 cells. SCC-4 and SCC-25 cells were not treated as negative control (NC) or treated with 20 µM PF-4708671 for 6 h (6 h), 12 h (12 h), 18 h (18 h), 1 day (1 d), 2 days (2 d), and 3 days (3 d). Western blot analysis was performed to examine the expression levels of p-mTOR, mTOR, p-p70S6K, p70S6K, and β-actin.	28626016 30423811
Growth inhibition assay	Cell viability; PubMed: 30423811 Int J Mol Sci Inhibitory effects of various doses (0.5, 1, 2, 5, 10, 20, and 40 µM) of PF-4708671 on SCC-4 (B) and SCC-25 (C) cells were assessed using MTT assay after 72 h of treatment. Data presented are the mean and standard error of the mean of three independent experiments. * p < 0.05, p < 0.01, and * p < 0.001 indicate the statistical significance of differences between cells with and without treatment. t (red and * for SCC-4 and blue , * and *** for SCC-25).	30423811

Protocol

References

[1] Pearce LR, et al. Biochem J, 2010, 431(2), 245-255.

Solubility (25°C)

In vitro	DMSO	30 mg/mL (76.84 mM)
	Ethanol	8 mg/mL (20.49 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 30% PEG400+0.5% Tween80+5% propylene glycol For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download PF-4708671 SDF

Molecular Weight	390.41
Formula	C₁₉H₂₁F₃N₆
CAS No.	1255517-76-0
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Whether the in vivo formula "30% PEG400+0.5% Tween80+5% Propylene glycol" for S2163 is suitable for i.p. or not?
Answer:
The formula "30% PEG400+0.5% Tween80+5% Propylene glycol" on our website is an oral one. It is a suspension.

S6 Kinase Signaling Pathway Map

Related S6 Kinase Products

LY2584702 ^New

LY2584702 is a selective, ATP-competitive p70S6K inhibitor with IC50 of 4 nM. Phase 1.
LY2584702 Tosylate ^New

LY2584702 Tosylate is a selective, ATP-competitive p70S6K inhibitor with IC50 of 4 nM. Phase 1.
CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs.
BI-D1870

BI-D1870 is an ATP-competitive inhibitor of S6 ribosome for RSK1/2/3/4 with IC50 of 31 nM/24 nM/18 nM/15 nM in cell-free assays, respectively; 10- to 100-fold selectivity for RSK than MST2, GSK-3β, MARK3, CK1 and Aurora B.
Rapamycin (Sirolimus)

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
MK-2206 2HCl

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.

Features:The first allosteric small molecule inhibitor of Akt to enter clinical development.
CHIR-99021 (CT99021) HCl

CHIR-99021 HCl (CT99021) is hydrochloride of CHIR-99021, which is a GSK-3α/β inhibitor with IC50 of 10 nM/6.7 nM; CHIR-99021 shows greater than 500-fold selectivity for GSK-3 versus its closest homologs Cdc2 and ERK2.
LY294002

LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. Solutions of 3-MA are best fresh-prepared by heating.
Everolimus (RAD001)

Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay.

Choose Your Country or Region

By Signaling Pathways

By product type

PF-4708671

Cited by 14 Publications

5 Customer Reviews

Purity & Quality Control

Choose Selective S6 Kinase Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download PF-4708671 SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

S6 Kinase Signaling Pathway Map

Related S6 Kinase Products

Choose Your Country or Region

By Signaling Pathways

By product type

PF-4708671

Cited by 14 Publications

5 Customer Reviews

Purity & Quality Control

Choose Selective S6 Kinase Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download PF-4708671 SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

S6 Kinase Signaling Pathway Map

Related S6 Kinase Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)